Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
第1/2相
完了
NCT03141060
| 対象疾患 | Tuberculosis, HIV Infections |
|---|
| 相 | 第1/2相 |
|---|
| スポンサー | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 37 名 |
|---|
| 介入（薬剤） | Delamanid, Optimized multidrug background regimen (OBR) for children with MDR-TB |
|---|
| 開始日 | 2019年2月18日 |
|---|
| 完了日 | 2025年4月22日 |
|---|
| 結果公開日 | 2026年6月25日 |
|---|
概要
This Phase I/II study evaluated the pharmacokinetics, safety, and tolerability of the anti-tuberculosis (TB) drug delamanid (DLM) in combination with an optimized multidrug background regimen (OBR) for multidrug-resistant tuberculosis (MDR-TB) in children with MDR-TB with and without HIV.
Percentage of Participants With Adverse Events of ≥ Grade 3 Severity
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 18.2 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 25.0 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 33.3 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 25.0 percentage of participants |
|---|
Percentage of Participants With Adverse Events of ≥ Grade 3 Assessed by the Core Team to be at Least Possibly Related to the Study Drug
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 9.1 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 25.0 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 0.0 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 0.0 percentage of participants |
|---|
Percentage of Participants Who Were Terminated From Study Treatment Due to a Drug-related Adverse Event
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 9.1 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 12.5 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 0.0 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 0.0 percentage of participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。